ENDP Endo International plc

5.46
-0.11  -2%
Previous Close 5.57
Open 5.6
52 Week Low 2.08
52 Week High 7.1
Market Cap $1,257,396,116
Shares 223,103,410
Float 162,189,931
Enterprise Value $7,871,530,724
Volume 2,670,693
Av. Daily Volume 5,418,832
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
QWO
Edematous fibrosclerotic panniculopathy (“cellulite”)
Approved
Approved
FDA Approval announced July 6, 2020.
AVEED (testosterone undecanoate) intramuscular injection
Men diagnosed with hypogonadism
Approved
Approved
CRL issued May 30 2013. Approved March 6 2014.
BEMA Buprenorphine
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate
Approved
Approved
Approved October 26, 2015.

Latest News

  1. WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (Endo) for approximately $658.2 million in equity value.

    Endo's all-cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported…

    WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (Endo) for approximately $658.2 million in equity value.

    Endo's all-cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6,159,975 shares of BioSpecifics' common stock were validly tendered and not validly withdrawn, representing approximately 82.8% of the outstanding shares of BioSpecifics' common stock on a fully diluted basis. All of the conditions to the Offer have been satisfied, and on December 2, 2020, Endo accepted for payment, and will as promptly as practicable pay for, all shares validly tendered and not validly  withdrawn.

    The acquisition was completed on December 2, 2020 through a merger of Beta Acquisition Corp., Endo's wholly-owned indirect subsidiary, with and into BioSpecifics, with BioSpecifics continuing as the surviving entity, in accordance with Section 251(h) of the Delaware General Corporation Law without a vote of BioSpecifics' stockholders. In connection with the merger, shares of BioSpecifics that were not tendered prior to the expiration of the Offer were converted into the right to receive consideration of $88.50 per share. As a result of the completion of the merger, BioSpecifics' common stock will be delisted from The Nasdaq Global Market.

    About BioSpecifics Technologies Corp.

    BioSpecifics Technologies Corp. is a commercial-stage biopharmaceutical company. The Company discovered and developed a proprietary form of injectable collagenase ("CCH"), which is currently marketed by the Company's partner, Endo, as XIAFLEX® in North America for the treatment of Dupuytren's contracture and Peyronie's disease. Endo announced that it received FDA approval of CCH for the treatment of moderate to severe cellulite in the buttocks of adult women; Qwo™ is expected to be available commercially in the U.S. starting in the first half of 2021. The CCH research and development pipeline includes several additional potential indications including adhesive capsulitis and plantar fibromatosis. For more information, please visit www.biospecifics.com.

    About Endo International plc

    Endo International plc (NASDAQ:ENDP) is a specialty pharmaceutical company committed to helping everyone they serve live their best life through the delivery of quality, life-enhancing therapies. Endo's decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, Endo boldly transforms insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. For more information, please visit www.endo.com.

    Forward-Looking Statements 

    The statements included above that are not a description of historical facts are forward-looking statements. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would," or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the planned completion and timing of Endo's payment for the tendered shares, the delisting of the Company's common stock, the intent, belief, and current expectations of the Company and members of its senior management team and Board of Directors, potential indications, research and development plans, indications in development, and the occurrence and timing of the commercial launch of Qwo™. Risks and uncertainties that could cause results to differ from expectations include, without limitation: business effects, including the effects of industry, economic or political conditions outside of the Company's control; transaction costs; actual or contingent liabilities; the timing of regulatory filings and action; the ability of Endo to achieve its objectives for XIAFLEX® and Qwo™; the market for XIAFLEX® in, and timing, initiation, and outcome of clinical trials for, additional indications; the potential of XIAFLEX® to be used in additional indications; Endo modifying its objectives or allocating resources other than to XIAFLEX® and Qwo™; adverse impacts on business, operating results or financial condition in the future due to pandemics, epidemics or outbreaks, such as COVID-19; and risks and uncertainties pertaining to the Company's business, including, without limitation, the risks and uncertainties detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended September 30, 2020, and its other filings with the Securities and Exchange Commission.

    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law.

    Cision View original content:http://www.prnewswire.com/news-releases/biospecifics-announces-completion-of-acquisition-by-endo-pharmaceuticals-301183768.html

    SOURCE BioSpecifics Technologies Corp.

    View Full Article Hide Full Article
  2. DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired).

    "We're pleased to have completed the acquisition of BioSpecifics, which immediately enhances our adjusted EBITDA and the profitability profile of both XIAFLEX® and Qwo—two of our most durable and differentiated products with significant long-term growth potential," said Blaise Coleman, President and CEO of Endo.

    Endo has had a strategic relationship with BioSpecifics since 2004. Under the terms of the relationship, BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals, for the treatment of Dupuytren's contracture and Peyronie's disease, and QWO, the first FDA-approved injectable treatment for cellulite, which is expected to be launched by Endo Aesthetics in spring 2021.

    Transaction Details

    Endo completed the transaction through a tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics, at a price of $88.50 per Share (the "Offer Price"), net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"), and the subsequent merger of Merger Sub with and into BioSpecifics. Endo commenced the Offer on November 2, 2020, and the Offer expired at one minute after 11:59 PM, New York time, on December 1, 2020. As of the expiration of the Offer, approximately 6,159,975 Shares were validly tendered and not validly withdrawn in accordance with the terms of the Offer, representing approximately 82.8% of the Shares on a fully diluted basis, and such shares were accepted for payment under the terms of the Offer.

    Following the completion of the Offer, Endo completed the merger of Merger Sub with and into BioSpecifics in accordance with Section 251(h) of the Delaware General Corporation Law, in which the Shares that were not tendered in the Offer were acquired by Endo and cancelled and converted into the right to receive the Offer Price.  As a result of the merger, BioSpecifics ceased to be a publicly traded company and became a wholly-owned subsidiary of Endo.

    About Endo International plc

    Endo International plc is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Learn more at www.endo.com or connect with us on LinkedIn.

    Cautionary Statement on Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. These forward-looking statements include, among others, the statements by Mr. Coleman, as well as statements relating to Endo's acquisition and integration of BioSpecifics and Endo's future financial performance, business prospects and strategy. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the acquisition or integration of BioSpecifics, difficulties or unanticipated expenses relating to the acquisition or integration, the possibility that anticipated synergies and other benefits of the acquisition or integration will not be realized in the amounts anticipated, within the expected timeframe or at all, the effect of the  acquisition and integration on business relationships, competition, including technological advances, new products and patents attained by competitors, challenges to patents, challenges inherent in product research and development, clinical trial outcomes and quality, availability and affordability of products, and other circumstances beyond Endo's control. You should not place undue reliance on these forward-looking statements. Additional information concerning these and other risk factors can be found in Endo's reports filed with securities regulators in Canada and in the companies' reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/endo-completes-acquisition-of-biospecifics-301183698.html

    SOURCE Endo International plc

    View Full Article Hide Full Article
  3. DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that the Company will participate in two investor conferences.

    Members of management will participate in the 2020 Bank of America Leveraged Finance Virtual Conference on Monday, November 30, 2020 at 8:15 a.m. ET and the Piper Sandler 32nd Annual Virtual Healthcare Conference being held November 30 - December 3, 2020.

    2020 Bank of America Leveraged Finance Virtual Conference
    A live webcast and audio archive for the Bank of America Leveraged Finance Virtual Conference fireside chat will be available on the Company's website at http://investor.endo.com/events-and-presentations. Participants should allow approximately 10 minutes prior to the presentation's…

    DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that the Company will participate in two investor conferences.

    Members of management will participate in the 2020 Bank of America Leveraged Finance Virtual Conference on Monday, November 30, 2020 at 8:15 a.m. ET and the Piper Sandler 32nd Annual Virtual Healthcare Conference being held November 30 - December 3, 2020.

    2020 Bank of America Leveraged Finance Virtual Conference

    A live webcast and audio archive for the Bank of America Leveraged Finance Virtual Conference fireside chat will be available on the Company's website at http://investor.endo.com/events-and-presentations. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

    Piper Sandler 32nd Annual Virtual Healthcare Conference

    Beginning November 23, 2020, the Piper Sandler Virtual Healthcare Conference pre-recorded fireside chat will be available on the Company's website at http://investor.endo.com/events-and-presentations for 90 days. Participants should download any streaming media software needed to listen to the Internet webcast.

    About Endo International plc

    Endo International plc (NASDAQ:ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Learn more at www.endo.com or connect with us on LinkedIn.

     

    Cision View original content:http://www.prnewswire.com/news-releases/endo-to-participate-in-upcoming-investor-conferences-301176088.html

    SOURCE Endo International plc

    View Full Article Hide Full Article
  4. DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (NASDAQ:BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer, which commenced on November 2, 2020, is…

    DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (NASDAQ:BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer, which commenced on November 2, 2020, is being made pursuant to the previously announced Agreement and Plan of Merger, dated October 19, 2020, by and among Endo, Merger Sub and BioSpecifics (as it may be amended from time to time, the "Merger Agreement").

    With the expiration of the waiting period under the HSR Act, the transaction is expected to close in early December 2020, subject to the satisfaction of all remaining closing conditions set forth in the Merger Agreement. Unless extended or earlier terminated, the Offer is scheduled to expire at one minute after 11:59 PM, New York time, on December 1, 2020, which is the 20th business day following the commencement of the Offer.

    Following the completion of the Offer, Endo expects to consummate a merger of Merger Sub with and into BioSpecifics as soon as practicable, in which Shares that have not been tendered in the Offer will be acquired by Endo and cancelled and converted into the right to receive the Offer Price. The Merger Agreement was approved by the Boards of Directors of both Endo and BioSpecifics. The BioSpecifics Board of Directors has recommended that BioSpecifics' stockholders tender their Shares pursuant to the Offer.

    About Endo

    Endo International plc is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Learn more at www.endo.com or connect with us on LinkedIn.

    Additional Information and Where to Find It

    This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of common of BioSpecifics or any other securities. The solicitation and the Offer has been made pursuant to a tender offer statement on Schedule TO, as amended, including an offer to purchase, a letter of transmittal and other related documents that Endo has filed with the Securities and Exchange Commission (the "SEC"). In addition, BioSpecifics filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9, as amended, with the SEC with respect to the Offer. The Offer to purchase the Shares will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO, as amended. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9  CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS OF BioSpecifics ARE URGED TO READ CAREFULLY BECAUSE THE OFFER MATERIALS CONTAIN IMPORTANT INFORMATION SUCH STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The tender offer materials and the Solicitation/Recommendation Statement are available free of charge at the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by Endo are available free of charge on Endo's website. In addition, security holders of BioSpecifics may obtain free copies of the tender offer materials by contacting the information agent for the Offer that has been named in the Tender Offer Statement on Schedule TO. Copies of the documents filed with the SEC by BioSpecifics are available free of charge on BioSpecifics' website.

    Cautionary Statement on Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. These forward-looking statements include, among others, statements relating to Endo's or BioSpecifics' future financial performance, business prospects and strategy, including the Offer, the Merger, the ability to successfully complete such transactions and other similar matters. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the Offer and the Merger, including, among other things, regarding how many of BioSpecifics' stockholders will tender their shares in the tender offer, the possibility that competing offers will be made, the ability to obtain requisite regulatory approvals relating to the acquisition, the ability to satisfy the conditions to the closing of the Offer and the Merger, the expected timing of the Offer and the Merger, the risk of stockholder litigation relating to the transaction, including resulting expense or delay, difficulties or unanticipated expenses in connection with integrating BioSpecifics' operations into Endo's and the possibility that anticipated synergies and other benefits of the transaction will not be realized in the amounts anticipated, within the expected timeframe or at all, the effect of the announcement of the Offer and the Merger on Endo's and BioSpecifics' business relationships, competition, including technological advances, new products and patents attained by competitors, challenges to patents, the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, the expected tax treatment of the transaction, challenges inherent in product research and development, clinical trial outcomes and quality, availability and affordability of products, and other circumstances beyond Endo's and BioSpecifics' control. You should not place undue reliance on these forward-looking statements. Certain of these and other risks and uncertainties are discussed in Endo's and BioSpecifics' filings with the SEC and, in Endo's case, with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including the Schedule TO, as amended (including the offer to purchase, letter of transmittal and related documents) Endo filed with the SEC, the Solicitation/Recommendation Statement on Schedule 14D-9, as amended BioSpecifics filed with the SEC and their respective Form 10-Ks and 10-Qs under the caption "Risk Factors" and as otherwise enumerated therein. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/endo-announces-expiration-of-hart-scott-rodino-waiting-period-for-biospecifics-tender-offer-301175494.html

    SOURCE Endo International plc

    View Full Article Hide Full Article
  5. Vizient, Inc. announces that it has published an update to its list of essential medications which, if not available, would prove the greatest threat to hospitals' ability to provide immediate and high-quality patient care. The update adds 13 medications bringing the total identified drugs to 225. The complete list of essential medications is here.

    "The identification and recognition of these drugs as essential by our hospital members and clinical experts is another key action step Vizient takes to improve the resilience of the pharmaceutical supply chain. We will continue to update our list quarterly and share it as part of our commitment to working with our members and other stakeholders to bring a permanent end to drug shortages," said…

    Vizient, Inc. announces that it has published an update to its list of essential medications which, if not available, would prove the greatest threat to hospitals' ability to provide immediate and high-quality patient care. The update adds 13 medications bringing the total identified drugs to 225. The complete list of essential medications is here.

    "The identification and recognition of these drugs as essential by our hospital members and clinical experts is another key action step Vizient takes to improve the resilience of the pharmaceutical supply chain. We will continue to update our list quarterly and share it as part of our commitment to working with our members and other stakeholders to bring a permanent end to drug shortages," said Dan Kistner, PharmD, group senior vice president, pharmacy solutions for Vizient.

    The newly added drugs are: amino acid injection, ascorbic acid injection, chromic chloride injection, clindamycin phosphate injection, doxycycline hyclate injection, lidocaine hydrochloride injection, lidocaine hydrochloride/ epinephrine bitartrate injection, manganese injection, pegaspargase injection, sodium acetate injection, sulfamethoxazole/trimethoprim oral, tocilizumab injection and Vitamin D analogs pharmacologic category.

    To compile and update the list, Vizient's pharmacy experts conduct a comprehensive review of the World Health Organization's Essential Medicines list, the Advanced Cardiac Life Support and Pediatric Advanced Life Support algorithms and medications included in Vizient member health systems' critical drug lists. The medications on the Vizient list fall into one of three categories:

    • Acute life-saving drugs with no alternatives (72 drugs) — used in acute and critical circumstances to sustain life and for which there are no current alternatives
    • Chronic life-saving drugs with no alternatives (30 drugs) — used in chronic disease states or conditions where no alternatives are available (e.g., chemotherapy medications)
    • High impact drugs (123 drugs) — alternative medications are available but may be less clinically desirable and/or are more operationally difficult to use; also reflects drugs where the absence of one medication can affect therapeutically related drugs.

    Of the 219 drugs designated by Vizient as essential, over 46% are currently included in its Novaplus® private label program, including more than 50% of the identified high-impact drugs.

    Additionally, Vizient has expanded its Novaplus Enhanced Supply program to include multi-dose Adrenalin® (epinephrine injection), from Par Pharmaceutical, a subsidiary of Endo International plc (NASDAQ:ENDP), and dexmedetomidine premix presentation from Baxter. Epinephrine is part of the acute life-saving drug category and dexmedetomidine is part of the high-impact drug category of the Essential Medications list. Epinephrine is used to treat anaphylaxis and cardiac arrest. Dexmedetomidine is used in the management of intubated and ventilated patients including those with COVID.

    For medications in the Novaplus Enhanced Supply program, the contracted supplier is required to maintain additional, onshore inventory based on the historical usage of Vizient members. This program includes 19 drugs on Vizient's essential medications list and has resulted in 39 million additional units of essential medications in the U.S. health care supply chain.

    About Vizient, Inc.

    Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation's acute care providers, which includes 95% of the nation's academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World's Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

    About Vizient Novaplus and the Novaplus Enhanced Supply Program

    Novaplus, a Vizient sourcing program, is the market-leading, private label program that includes a consistent supply of competitively priced medications for both inpatient and outpatient facilities. Novaplus is also a critical strategy in protecting Vizient health system and hospital members from drug shortages and the impact on resources and delivery of patient care.

    Novaplus Enhanced Supply Program contracted suppliers provide additional inventory of essential products to mitigate supply disruptions and demand surge. Contract terms provide greater predictability and sustainability to drive continued production and supply resiliency. Production transparency requirements increase visibility to anticipate and further mitigate potential supply disruptions. By purchasing through Novaplus Enhanced Supply, health care facilities also receive expanded value and benefits built on the foundation of the industry's longest-run private label program.

    View Full Article Hide Full Article
View All Endo International plc News